HIMS - Hims & Hers: Compounded Semaglutide Boost Unlikely To Last - Moderate Risks Ahead
2024-06-13 16:00:00 ET
Summary
- HIMS has proven that a telehealth platform can remain relevant in a rapidly changing landscape, by opting to cater to the retail healthcare market through customized prescription/ over-the-counter medications.
- This is attributed to its in-house pharmacy, online dermatologist capability, and strong focus on subscription-based consumer service across sexual health, skincare, mental health, hair care, and weight loss care.
- Combined with the partnership with a leading US manufacturer of generic medications, HIMS has also marketed its compounded semaglutide products - tapping into the massive unmet patient demand.
- However, it is uncertain if the compounded semaglutide products marketed actually comply with the US FDA guidelines, as NVO and LLY also embark on multiple lawsuits.
- Despite the impressive growth estimates, HIMS remains highly shorted as the management also unlocks great gains at these inflated levels - triggering a minimal margin of safety.
HIMS Has Successfully Differentiated Itself As A Retail Healthcare Telemedicine Platform
We previously covered Teladoc ( TDOC ), discussing the troubling signs of declining memberships and worsening profitability, with it remaining to be seen if the downtrend might persist as the telemedicine market competition intensified and the COVID-19 pandemic ended....
Hims & Hers: Compounded Semaglutide Boost Unlikely To Last - Moderate Risks Ahead